Richard Schilsky to Leukopenia
This is a "connection" page, showing publications Richard Schilsky has written about Leukopenia.
Connection Strength
0.122
-
Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study. J Clin Oncol. 1995 Mar; 13(3):741-7.
Score: 0.032
-
Paradoxical relationship between acetylator phenotype and amonafide toxicity. Clin Pharmacol Ther. 1991 Nov; 50(5 Pt 1):573-9.
Score: 0.025
-
Cytarabine-cis-platin interactions in patients with advanced cancer. Semin Oncol. 1985 Jun; 12(2 Suppl 3):171-6.
Score: 0.016
-
Clinical pharmacology of methotrexate. Cancer Treat Rep. 1981; 65 Suppl 1:51-4.
Score: 0.012
-
Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin. Cancer Chemother Pharmacol. 1997; 39(3):227-32.
Score: 0.009
-
Etoposide combined with interferon alfa-2b: novel exploitation of established etoposide pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 1996 Mar; 59(3):349-59.
Score: 0.009
-
Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender. Pharmacogenetics. 1996 Feb; 6(1):93-101.
Score: 0.009
-
Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456). Cancer Res. 1994 Jan 01; 54(1):114-9.
Score: 0.007
-
Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep. 1979 Sep-Oct; 63(9-10):1527-31.
Score: 0.003